Nonvitamin, Nonmineral Dietary Supplement Use among Adults with Fibromyalgia: United States, 2007–2012

Table 3

NVNM use in two nationally representative samples of adults with diagnosed fibromyalgia, National Health Interview Survey (NHIS 2007 = 221 () versus NHIS 2012 = 524 ()).

Characteristic	2007			2012			Overall
	(%)	95% CI	Weighted population estimate	(%)	95% CI	Weighted population estimate
NVNM use ever							<0.0001
Yes	114 (57.1)	(49.3, 64.9)	624881	204 (40.6)	(35.3, 45.8)	633029
No	107 (42.9)	(35.1, 50.7)	469162	320 (59.4)	(54.2, 64.7)	927192
NVNM use in past 12 months							<0.0001
Yes	82 (41.7)	(33.3, 50.2)	456477	157 (31.2)	(26.1, 36.4)	487362
No	139 (58.3)	(49.8, 66.7)	637566	367 (68.8)	(63.6, 73.9)	1072859
NVNM use in past 30 days							<0.0001
Yes	62 (32.7)	(24.6, 40.9)	358265	126 (24.5)	(19.9, 29.1)	382285
No	159 (67.3)	(59.1, 75.4)	735778	398 (75.5)	(70.9, 80.1)	1177936
Number of different NVNM supps in past 30 days
(Mean (SE))	0.99 (0.20)	(0.60, 1.4)		1.07 (0.38)	(0.32, 1.8)		0.894
Physician disclosure of NVNM							<0.0001
Yes	50 (64.6)	(53.1, 76.1)	294988	51 (71.4)	(59.0, 83.9)	140681
No	32 (35.4)	(23.9, 46.9)	161489	15 (28.6)	(16.1, 41.0)	56221

Note. Total sample with fibromyalgia is percentage denominator; adjusted for age, sex, and race/ethnicity based on 2000 Census data; adjusted for age, sex, and race/ethnicity based on 2010 Census data; significant changes between 2007 and 2012 indicated by nonoverlapping weighted population confidence intervals; values obtained by comparing weighted estimates; note: significant changes between datasets with differing weighting schemes indicated by nonoverlapping weighted population confidence intervals as ; among NVNM users with fibromyalgia; including combination NVNM supplement; within past 30 days ( = 66; 2007); only disclosure of top therapy assessed within past 12 months (2012); (95% CI: 1.1, 1.5); (95% CI: 1.6, 1.9).